Presentation is loading. Please wait.

Presentation is loading. Please wait.

APLCC POSTER SESSION 2 - WEDNESDAY, NOVEMBER 28

Published byJessie Wiggins Modified over 4 years ago

Similar presentations

Presentation on theme: "APLCC POSTER SESSION 2 - WEDNESDAY, NOVEMBER 28"— Presentation transcript:

1 APLCC POSTER SESSION 2 - WEDNESDAY, NOVEMBER 28
Journal of Thoracic Oncology  Volume 7, Issue 11, Pages S483-S504 (November 2012) DOI: /01.JTO Copyright © 2012 International Association for the Study of Lung Cancer Terms and Conditions

2 Figure 1 Overall survival
Journal of Thoracic Oncology 2012 7, S483-S504DOI: ( /01.JTO ) Copyright © 2012 International Association for the Study of Lung Cancer Terms and Conditions

3 Figure 2 Progression free survival
Journal of Thoracic Oncology 2012 7, S483-S504DOI: ( /01.JTO ) Copyright © 2012 International Association for the Study of Lung Cancer Terms and Conditions

4 Figure 1 Journal of Thoracic Oncology 2012 7, S483-S504DOI: ( /01.JTO ) Copyright © 2012 International Association for the Study of Lung Cancer Terms and Conditions

5 Figure 2 Overall survival curves of 738 NSCLC patients who were performed VATS lobectomy. Journal of Thoracic Oncology 2012 7, S483-S504DOI: ( /01.JTO ) Copyright © 2012 International Association for the Study of Lung Cancer Terms and Conditions

6 Journal of Thoracic Oncology 2012 7, S483-S504DOI: (10. 1097/01. JTO
Copyright © 2012 International Association for the Study of Lung Cancer Terms and Conditions

7 Figure 1 Procedure of CT-TBB
Journal of Thoracic Oncology 2012 7, S483-S504DOI: ( /01.JTO ) Copyright © 2012 International Association for the Study of Lung Cancer Terms and Conditions

8 Journal of Thoracic Oncology 2012 7, S483-S504DOI: (10. 1097/01. JTO
Copyright © 2012 International Association for the Study of Lung Cancer Terms and Conditions

9 Journal of Thoracic Oncology 2012 7, S483-S504DOI: (10. 1097/01. JTO
Copyright © 2012 International Association for the Study of Lung Cancer Terms and Conditions

10 Journal of Thoracic Oncology 2012 7, S483-S504DOI: (10. 1097/01. JTO
Copyright © 2012 International Association for the Study of Lung Cancer Terms and Conditions

11 Journal of Thoracic Oncology 2012 7, S483-S504DOI: (10. 1097/01. JTO
Copyright © 2012 International Association for the Study of Lung Cancer Terms and Conditions

12 Journal of Thoracic Oncology 2012 7, S483-S504DOI: (10. 1097/01. JTO
Copyright © 2012 International Association for the Study of Lung Cancer Terms and Conditions

Download ppt "APLCC POSTER SESSION 2 - WEDNESDAY, NOVEMBER 28"

Similar presentations

Massive Bronchogenic Cyst Joseph B. Levin, BA, Chi Wan Koo, MD, Jessica S. Donington, MD Journal of Thoracic Oncology Volume 5, Issue 11, Pages 1862-1863.

Massive Bronchogenic Cyst Joseph B. Levin, BA, Chi Wan Koo, MD, Jessica S. Donington, MD Journal of Thoracic Oncology Volume 5, Issue 11, Pages
A2-06: Survival differences for non-Bronchioloalveolar Carcinoma (BAC) non-small-cell lung cancer (NSCLC) cases with ipsilateral intrapulmonary metastasis.

A2-06: Survival differences for non-Bronchioloalveolar Carcinoma (BAC) non-small-cell lung cancer (NSCLC) cases with ipsilateral intrapulmonary metastasis.
High Discrepancy of Driver Mutations in Patients with NSCLC and Synchronous Multiple Lung Ground-Glass Nodules  Chunyan Wu, MD, Chao Zhao, MD, Yang Yang,

High Discrepancy of Driver Mutations in Patients with NSCLC and Synchronous Multiple Lung Ground-Glass Nodules  Chunyan Wu, MD, Chao Zhao, MD, Yang Yang,
Phase II Study of Gefitinib, an Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor (EGFR-TKI), and Celecoxib, a Cyclooxygenase-2 (COX-2) Inhibitor,

Phase II Study of Gefitinib, an Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor (EGFR-TKI), and Celecoxib, a Cyclooxygenase-2 (COX-2) Inhibitor,
Prognostic Significance of the Number of Lymph Nodes Removed at Lobectomy in Stage IA Non-small Cell Lung Cancer  Sai-Hong Ignatius Ou, MD, PhD, Jason.

Prognostic Significance of the Number of Lymph Nodes Removed at Lobectomy in Stage IA Non-small Cell Lung Cancer  Sai-Hong Ignatius Ou, MD, PhD, Jason.
SC17.02 Lung Cancer in China: Challenges and Perspectives

SC17.02 Lung Cancer in China: Challenges and Perspectives
ALK FISH and IHC: You Cannot Have One without the Other

ALK FISH and IHC: You Cannot Have One without the Other
Validation of the Stage Groupings in the Eighth Edition of the TNM Classification for Lung Cancer  Xizhao Sui, MD, Wei Jiang, MD, Haiqing Chen, MD, Fan.

Validation of the Stage Groupings in the Eighth Edition of the TNM Classification for Lung Cancer  Xizhao Sui, MD, Wei Jiang, MD, Haiqing Chen, MD, Fan.
A Randomized, Phase 2 Trial of Docetaxel with or without PX-866, an Irreversible Oral Phosphatidylinositol 3-Kinase Inhibitor, in Patients with Relapsed.

A Randomized, Phase 2 Trial of Docetaxel with or without PX-866, an Irreversible Oral Phosphatidylinositol 3-Kinase Inhibitor, in Patients with Relapsed.
APLCC ORAL ABSTRACT SESSIONS - MONDAY, NOVEMBER 26

APLCC ORAL ABSTRACT SESSIONS - MONDAY, NOVEMBER 26
Susan C. Scott, MD, Nathan A. Pennell, MD, PhD 

Susan C. Scott, MD, Nathan A. Pennell, MD, PhD 
Complement and Correction for Meta-Analysis of Patients with Extensive-Stage Small Cell Lung Cancer Managed with Irinotecan/Cisplatin versus Etoposide/Cisplatin.

Complement and Correction for Meta-Analysis of Patients with Extensive-Stage Small Cell Lung Cancer Managed with Irinotecan/Cisplatin versus Etoposide/Cisplatin.
Significance of Programmed Cell Death-Ligand 1 Expression and its Association with Survival in Patients with Small Cell Lung Cancer  Hidenobu Ishii, MD,

Significance of Programmed Cell Death-Ligand 1 Expression and its Association with Survival in Patients with Small Cell Lung Cancer  Hidenobu Ishii, MD,
Joachim Pfannschmidt, MD, Hans Hoffmann, MD, Hendrick Dienemann, MD 

Joachim Pfannschmidt, MD, Hans Hoffmann, MD, Hendrick Dienemann, MD 
Ellen M. Schultz, MS, Gerard A. Silvestri, MD, MS, Michael K

Ellen M. Schultz, MS, Gerard A. Silvestri, MD, MS, Michael K
Outcomes of unexpected pathologic N1 and N2 disease after video-assisted thoracic surgery lobectomy for clinical stage I non–small cell lung cancer  Hong.

Outcomes of unexpected pathologic N1 and N2 disease after video-assisted thoracic surgery lobectomy for clinical stage I non–small cell lung cancer  Hong.
NA  Journal of Thoracic Oncology 

NA  Journal of Thoracic Oncology 
Electronic Updates for JTO Readers

Electronic Updates for JTO Readers
IA05.01 Lung Cancer Cases Journal of Thoracic Oncology

IA05.01 Lung Cancer Cases Journal of Thoracic Oncology
Central versus Peripheral Tumor Location: Influence on Survival, Local Control, and Toxicity Following Stereotactic Body Radiotherapy for Primary Non–Small-Cell.

Central versus Peripheral Tumor Location: Influence on Survival, Local Control, and Toxicity Following Stereotactic Body Radiotherapy for Primary Non–Small-Cell.

Similar presentations

Ads by Google